Two years ago, Uncoded set out with a simple but ambitious idea: that India didn't just need access to the world's best genomics tools - it needed the capability to build its own. Today, that idea has grown into a fast-moving portfolio of indigenous NGS kits, gene panels, and multi-omics workflows, and a track record that has quietly reshaped how Indian researchers think about "Make in India" science. Born out of Premas Life Sciences Pvt. Ltd., a company with a 20-year legacy of introducing global genomics leaders like Illumina, Cytek Biosciences, Olink, Bruker Spatial Biology and Covaris to Indian labs - Uncoded represents a deliberate shift in ambition: from being India's gateway to global innovation, to becoming an innovator in its own right. The brand's first product, the 16S V3–V4 Library Preparation Kit, answered a real and immediate need: high-accuracy microbial profiling built for Indian labs and Indian budgets, without compromising on the rigor global researchers expect. It was proof of concept for everything that followed. In the two years since, Uncoded has built out a portfolio squarely focused on oncology and infectious disease detection, the HPV-STI Genomap, BRCA 1/2 Panel, Myeloid Profiler DNA and RNA Panels, Glaucoma Panel, and the HRR panel. Alongside these, OmniPreserve rounds out the portfolio as Uncoded's answer to reliable sample storage and preservation. Together, these solutions address some of the most pressing gaps in clinical and translational genomics in India today. The traction has matched the ambition. In just two years since inception, Uncoded has gone on to serve more than 100 customers, a signal that India's research and clinical community was ready for homegrown tools that don't ask them to compromise on quality. Uncoded is now also extending its footprint beyond Indian borders, taking its first steps into overseas markets and ensuring that solutions built in India are engineered to meet global standards. What sets this journey apart is not just the speed of the product roadmap, but the model behind it: close, active collaboration with clinicians, academic labs, startups, and pharmaceutical researchers, each helping shape tools that solve real, on-the-ground scientific problems rather than theoretical ones. Backed by local manufacturing, robust quality systems, and hands-on technical support, Uncoded has worked to earn something harder to build than a product line - trust. Much of this progress has been shaped in partnership with some of India's and the world's leading research and clinical institutions. Collaborations with CDFD, IGIB, and NIBMG have helped ground Uncoded's assay development in rigorous, India-relevant science, while the partnership with the University of Salford has brought an international lens to the table. On the clinical side, work alongside Amrita Hospital, Faridabad, and Adyar Cancer Institute has kept Uncoded's oncology and infectious disease solutions tied closely to real patient and diagnostic needs, ensuring that what gets built in the lab translates into tools clinicians can actually use. These partnerships reflect Uncoded's underlying philosophy: that the best local content and the most targeted, customised solutions are born not in isolation, but in genuine collaboration with the people closest to the problem. Two years in, the story is still early. But it is unmistakably a story of momentum: a small, focused team turning a vision of scientific self-reliance into tangible tools that are already in the hands of over 100 Indian customers, and increasingly, on the radar of the global genomics community. "Two years ago, Uncoded began with a conviction that India has the scientific talent and ambition to build genomics solutions the world can rely on, not just adopt them. Looking back, what fills me with the most pride isn't any single product, it's the trust that over 100 customers have placed in us in such a short time. Our 20-year legacy with Illumina taught us what excellence looks like; with Uncoded, we've spent the last two years proving that excellence can be built right here, in India and now, as we take our first steps into overseas markets, we're proving it can travel too. This anniversary isn't a finish line - it's a marker on a much longer journey toward making India a genuine source of genomics innovation for the world. We're just getting started." Praveen Gupta, Managing Director, Premas Life Sciences Pvt. Ltd. As Uncoded steps into its third year, its focus remains the same as it was on day one: build for India, hold the line on global standards, and keep listening to the researchers it exists to serve. To explore Uncoded’s innovations, visit: www.uncoded.in Watch the R&D video: www.uncoded.in/rd-video Follow us on LinkedIn: Uncoded LinkedIn | Premas Life Sciences LinkedIn For partnerships, product demos, or distributor queries, contact: uncoded@premaslifesciences.com About Uncoded Uncoded is a multi-omics solution brand by Premas Life Sciences Pvt Ltd, offering indigenous, high-quality kits and workflows in genomics, proteomics, and molecular biology. Built on Premas’ 20-year legacy of customer trust, innovation, and global partnerships, Uncoded aims to make cutting-edge science accessible, affordable, and impactful. About Premas Life Sciences Premas Life Sciences is one of India’s leading biotech companies, bringing breakthrough global technologies to Indian researchers for nearly two decades. With a focus on genomics, cell biology, proteomics, and automation, Premas represents several global leaders and now also pioneers its own product development through Uncoded. Disclaimer: The views and opinions expressed in the article are media marketing initiative and do not represent the stand and views of Mid-Day Group. Mid-Day Group disclaims any and all liability to any party, company or product for any direct, indirect, implied, punitive, special, incidental or consequential damages arising directly or indirectly from the use of this content.

The Mumbai-based AI-native Creative Studio Hits Million Dollar Valuation India’s entertainment industry is entering a new production age. Content demand is exploding across OTT, vertical video platforms, brand channels, creator ecosystems and global short-form networks. But the old production model is under pressure: timelines are shrinking, budgets are tightening, and platforms want more stories, in more formats, for more audiences. That is the market AIKONS is built for. Founded by Alii Khan, AIKONS is a Mumbai-based, human-led, AI-native creative studio and part of the broader Prachand Entertainment ecosystem. In less than a year, the company has gone from zero to a million-dollar valuation, positioning itself as one of India’s earliest serious AI-led content studios. While much of the AI-content world is still making teasers, trailers, visual tests and proof-of-concepts, AIKONS has moved several steps ahead. The studio has already created full-length feature films, complete micro-drama shows, and hours of AI-led narrative content designed for vertical OTT and digital-first platforms. Its work is not simply experimental; it is already being built for distribution, licensing and client delivery. AIKONS has developed original IPs and AI-led content properties available on leading vertical OTT platforms, while also building recurring and expanding engagements with some of the leading clients in India and globally. Its current and prospective client base spans entertainment platforms, music companies, content networks and brand-led storytelling mandates. The company’s rise comes at a moment when the economics of production are changing. AI is no longer just a creative novelty. Used well, it can compress timelines, reduce cost structures and unlock new formats that were previously too expensive or too slow to produce at scale. That is the core of AIKONS’ business model. AIKONS operates as a human-led AI studio. Writers, filmmakers, editors, producers and AI specialists remain at the centre of the creative process. AI is used as infrastructure: a way to build worlds faster, retain characters across episodes, create visual consistency, test formats, scale output and deliver cinematic ambition, with a creative signature. AIKONS’ bet is that the winners in this space will not be the companies using AI as a shortcut, but the studios that understand storytelling deeply enough to turn AI into a new production language. Inside the Prachand ecosystem, AIKONS has a natural advantage. Prachand brings live-action production, brand work, post-production, audio, editing, platform relationships and IP development experience. AIKONS adds a scalable AI-native engine. Together, they create a model where ideas can move from concept to script, from visual world to finished content, and from one format to many faster than traditional systems allow. This is why AIKONS million-dollar valuation is significant. It reflects more than one studio’s early success. It reflects a shift in how content companies may be valued in the AI era: not just by past revenue, but by their ability to create repeatable IP, scalable production systems, high-margin delivery, recurring client relationships and platform-ready output. AIKONS is already working in the space that many traditional studios are only beginning to study. The company’s AI-led production model is designed for vertical dramas, micro-series, long-form films, music-led video content, branded storytelling and original cinematic universes. Its internal margin targets are materially higher than traditional production, with AI-led projects designed to deliver stronger profitability through lower production cost and faster turnaround. In less than a year, that combination has taken AIKONS from zero to a million-dollar valuation. But the bigger story is what comes next. India’s AI content economy is still early, and global demand for scalable stories is only increasing. Platforms need volume. Brands need speed. Audiences need freshness. Production houses need better economics. AIKONS sits directly at that intersection. www.aikons.ai www.aikons.ai/work www.prachandentertainment.com Disclaimer: The views and opinions expressed in the article are media marketing initiative and do not represent the stand and views of Mid-Day Group. Mid-Day Group disclaims any and all liability to any party, company or product for any direct, indirect, implied, punitive, special, incidental or consequential damages arising directly or indirectly from the use of this content.